REFORM-HF Pivotal Trial of Aquapass Eccon System for Fluid Overload Management Completes Enrollment

August 10, 2026—Aquapass, developer of a noninvasive, kidney-independent therapy for fluid overload management in patients experiencing heart failure and chronic or end-stage kidney disease, announced completion of enrollment in the FDA pivotal REFORM-HF trial for its Eccon system.

P&F Products & Features Acquires AVVie

August 7, 2026—P&F Products & Features GmbH, headquartered in Vienna, Austria, announced the acquisition of AVVie GmbH, developer of the AngelValve augmentation system, a transcatheter platform for the treatment of mitral valve disease in patients with limited or no treatment options.

SMARTFLOW Study of AngioInsight’s AngioAI+ Software Platform Begins Enrollment

August 7, 2026—AngioInsight Inc., a developer of artificial intelligence (AI)–powered cardiovascular diagnostics, announced the enrollment of the first patient in the SMARTFLOW clinical study of the company’s investigational AngioAI+ software platform.

Salus Scientific Closes Series A Financing to Support Occupational Wellness Platform

August 6, 2026—Salus Scientific Corporation announced the closing of its oversubscribed Series A financing, raising a total of $10.1 million.

ALARA+ Coalition Launches Toolkits to Accelerate Adoption of Enhanced Radiation Protection

August 6, 2026—The Society for Cardiovascular Angiography & Interventions (SCAI) and the Society of Interventional Radiology announced that the release of the ALARA+ (“As Low And As Light As Reasonably Achievable”) Coalition’s resources to help hospital leadership and decisionmakers implement enhanced radiation and occupational safety guidelines for clinicians and staff working in catheterization labs.

Jack Darby Named CEO of Circa Scientific

July 31, 2026—Circa Scientific, Inc., a developer of access technologies for structural heart and electrophysiology procedures, announced the appointment of Jack Darby as Chief Executive Officer.

CroíValve Appoints Jaime Wheeler as Chief Executive Officer

July 31, 2026—CroíValve announced the appointment of Jaime Wheeler as Chief Executive Officer.

VDyne Commences TriNova TTVR System’s TRIVITA US Pivotal Study

July 31, 2026—VDyne Inc. announced that the first patient has been enrolled in the TRIVITA United States investigational device exemption pivotal study of the company’s TriNova transcatheter tricuspid valve replacement (TTVR) system for the treatment for tricuspid regurgitation (TR).